New strategies in prostate cancer: Translating genomics into the clinic

48Citations
Citations of this article
100Readers
Mendeley users who have this article in their library.

Abstract

With the rapidly developing use of next-generation sequencing technologies, there has been a surge in our knowledge of the genomic landscape of prostate cancer and a movement toward developing a molecular subclassification system for the disease. With this new understanding comes great clinical potential, both for the development of biomarkers as well as new therapeutic targets. Herein, we highlight the potential clinical use of recent discoveries and how they fit into our current paradigm. We describe the challenges that lie ahead as we move from genomic sequencing toward routine clinical practice and adopt precision cancer care for patients with prostate cancer. © 2012 American Association for Cancer Research.

Cite

CITATION STYLE

APA

Beltran, H., & Rubin, M. A. (2013). New strategies in prostate cancer: Translating genomics into the clinic. Clinical Cancer Research, 19(3), 517–523. https://doi.org/10.1158/1078-0432.CCR-12-1452

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free